Pamela Lawrence Endreny is a partner in the New York office of Gibson Dunn and a Co-Chair of the firm’s Tax Practice Group.
Pamela represents clients in a broad range of U.S. tax matters. Her experience includes mergers and acquisitions, spin-offs, investment funds, joint ventures, financing, and capital markets transactions.
She has been repeatedly selected for inclusion in Chambers USA: America’s Leading Lawyers for Business and The Legal 500 US and was also named a Tax “MVP” by Law360.
Pamela is a member of the Executive Committee of the New York State Bar Association Tax Section. She is also a member of the Tax Forum and Private Investment Fund Tax Forum.
Significant representations include:
- Exxon Mobil Corporation on its redomestication to Texas;
- Modine, in a Reverse Morris Trust, including the spin-off and combination of Modine’s Performance Technologies business with Gentherm;
- AT&T in its $5.75 billion acquisition of substantially all of Lumen’s mass markets fiber business;
- Berkshire Residential Investments on the closing of its real estate debt fund, Berkshire Multifamily Credit Fund IV, L.P., with $1.86 billion in committed capital;
- Otro Capital on the closing of its inaugural sports buyout fund, Otro Capital Fund I, with $1.2 billion in committed capital;
- Hahn & Company on the closing of its Korea-focused buyout fund, Hahn & Company IV, with $3.4 billion in committed capital;
- Lennar Corporation on the spin-off of Millrose Properties, Inc.;
- VMware in its $61 billion acquisition by Broadcom;
- Ziff Davis in its spin-off of Consensus Cloud Solutions, Inc.;
- Wrexham AFC and its owners, Ryan Reynolds and Rob Mac, on Apollo Sports Capital’s minority investment in Wrexham AFC;
- A group led by Ryan Reynolds and Hugh Jackman on their acquisition of a controlling stake in Australia’s SailGP team, the Bonds Flying Roos;
- Merck on its $9.2 billion acquisition of Cidara Therapeutics, Inc.;
- Gyre Therapeutics, Inc., on its acquisition of Cullgen Inc. in an all-stock merger valued at approximately $300 million;
- 89bio, Inc., on its up to $3.5 billion sale to Roche Holdings, Inc.;
- XOMA Royalty on XenoTherapeutics, Inc. and Xeno Acquisition Corp.’s acquisition of Repare Therapeutics Inc.;
- Arrowhead Pharmaceuticals on an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead.
Capabilities
Credentials
Education:
- Columbia University - 1994 Juris Doctor
- Brown University - 1986 Bachelor of Arts
Admissions:
- Massachusetts Bar
- New York Bar